<DOC>
	<DOCNO>NCT01292031</DOCNO>
	<brief_summary>1 . To demonstrate colistin iv . inferior meropenem empiric treatment VAP regard final point primary efficacy : mortality 28 subsequent day clinical heal patient clinically evaluate . 2 . To compare safety treatment colistin v meropenem VAP . 3 . To compare microbiological efficacy treatment colistin v meropenem VAP</brief_summary>
	<brief_title>Trial Colistin Versus Meropenem Ventilator-associated Pneumonia ( VAP ) ( CR-GNB )</brief_title>
	<detailed_description>Study drug : Patients randomize 1:1 rate open label fashion two intervention : group 1 : colistin load dose follow colistin infusion iv/8h group 2 : meropenem 2 g/iv/ 8 h. The overall treatment time minimum 8 day . Follow-up visit perform baseline , 72 h , 8 day , end treatment , 28 day recruitment ICU discharge , hospital discharge death .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>Age â‰¥ 18 year clinical radiological criterion VAP . The woman childbearing age ( surgically sterilize period menarche 1 year menopause ) must negative test pregnancy urine time recruitment . The patient his/her legal representative must sign document informed consent approve Ethics Review Committee . Hypersensitivity two antimicrobial study ( colistin/meropenem ) . Renal insufficiency substitute treatment . Corporal weight &lt; 40 kg &gt; 150 kg . Patients previously include another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>VAP</keyword>
	<keyword>MDR-GNB</keyword>
	<keyword>colistin</keyword>
	<keyword>meropenem</keyword>
</DOC>